Form 4: Gyre Therapeutics President Sells Shares Under 10b5-1 Trading Plan

Songjiang Ma, President of Gyre Therapeutics, sold 174 shares of common stock at $10.00 per share under a pre-arranged 10b5-1 trading plan.

Summary

• On March 21, 2025, Songjiang Ma, President of Gyre Therapeutics, sold 174 shares of common stock.
• The sale was executed at a price of $10.00 per share.
• The transaction was conducted under a Rule 10b5-1 trading plan adopted on September 13, 2024.
• Following the transaction, Mr. Ma directly owns 174 shares and indirectly owns 2,824,844 shares through his spouse.
• The shares were sold in multiple transactions at prices ranging from $10.00 to $10.005.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing related to a pre-planned stock sale. It doesn't inherently indicate positive or negative sentiment.

Industry Context

Sales by company presidents are common and often pre-planned to avoid insider trading accusations. The use of a 10b5-1 plan suggests the sale was arranged well in advance.

Stakeholder Impact

• The sale of shares by a company president could be perceived negatively by some shareholders, but the existence of a 10b5-1 plan mitigates this concern.

Key Dates

Keywords

Form 4, Gyre Therapeutics, Songjiang Ma, Stock Sale, 10b5-1 Trading Plan, Insider Trading